Investors / Nineteen Twenty-One
Nineteen Twenty-One
Venture capital
Nineteen Twenty-One is an early-stage venture fund led by Fredrik Debong that invests in companies addressing type 1 diabetes and related conditions. It invests first money in and up to select Series A rounds, working with a global network of clinicians, patients, researchers and investors.
Invests inHealthcare & Biotech
In its own wordstype 1 diabetesdigital healthbiotechhealthtechdiabetes care
Your fit with Nineteen Twenty-One
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNineteen Twenty-One lists 8 checked portfolio companies on its own site and is named in 1 funding round. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest themes are Healthcare & Biotech (78%), Fintech (11%) and Consumer (11%). 33% of its companies are based in United States. It invests most often alongside Calm/Storm Ventures, Fin Capital and Haymaker Ventures.
Counts come from funding rounds that name Nineteen Twenty-One, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 15th | 8 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 82th | 13% of companies confirmed by a round |
| Sector focus | 93th | 78% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Calm/Storm Ventures | 1 |
| Fin Capital | 1 |
| Haymaker Ventures | 1 |
| IT-Farm | 1 |
| PUSH Ventures | 1 |
| SETT | 1 |
| Scale Lab Andorra | 1 |
| Seedcamp | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers788%
- No longer answers00%
- Points to another company113%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 78% | 15% |
| Fintech | 11% | 12% |
| Consumer | 11% | 3% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Calm/Storm Ventures
Compare Nineteen Twenty-One head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
as stated on its siteRecent portfolio activity
when companies last raised with Nineteen Twenty-One| Date | Company | Stage |
|---|---|---|
| 27 Jul 2026 | Series A |
Round details for Nineteen Twenty-One
Amounts, full round histories and every co-investor in Nineteen Twenty-One's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
8 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
FintechHealthcare & Biotech | Portfolio page | |||
| The company develops a diabetes management app for people with diabetes. | Healthcare & Biotech | Portfolio page | ||
| NextCell Pharma develops groundbreaking stem cell therapies for the treatment of autoimmune and inflammatory diseases | Healthcare & Biotech | Portfolio page | ||
| Onalabs develops and provides innovative biometric technologies for monitoring health and optimizing performance in real-time. | Healthcare & Biotech | Jul 2026Series A | Page + round | |
| OneTwenty provides lab testing and device tracking services to monitor and manage health | Healthcare & Biotech | Portfolio page | ||
| The company provides management consulting services for strategy and innovation | Consumer | Portfolio page | ||
| Syntactiq provides an AI research platform for sensitive health data | Healthcare & Biotech | Portfolio page | ||
| T1D Scout offers at-home genetic screening for Type 1 Diabetes risk assessment | Healthcare & Biotech | Portfolio page |
About this data
site last read 7 Nov 2026- Site
- 1921.vc
- Last read
- 7 Nov 2026
- Watching since
- 7 Nov 2026
- Rounds since
- 27 Jul 2026
- Companies checked
- 8
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Nineteen Twenty-One's profile as data
Pull Nineteen Twenty-One's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/1921.vc
# also
GET /v1/firms/1921.vc/portfolio
GET /v1/firms/1921.vc/coinvestors
GET /v1/firms/1921.vc/news